Perbak Capital Partners LLP Acquires 6,547 Shares of ICU Medical, Inc. $ICUI

Perbak Capital Partners LLP increased its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 139.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,246 shares of the medical instruments supplier’s stock after buying an additional 6,547 shares during the quarter. Perbak Capital Partners LLP’s holdings in ICU Medical were worth $1,349,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. State Street Corp raised its position in ICU Medical by 3.2% in the second quarter. State Street Corp now owns 927,799 shares of the medical instruments supplier’s stock worth $122,609,000 after acquiring an additional 28,491 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of ICU Medical by 16.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 872,993 shares of the medical instruments supplier’s stock worth $104,718,000 after acquiring an additional 126,072 shares during the last quarter. Schroder Investment Management Group boosted its stake in shares of ICU Medical by 25.2% during the 3rd quarter. Schroder Investment Management Group now owns 796,704 shares of the medical instruments supplier’s stock worth $93,246,000 after acquiring an additional 160,380 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of ICU Medical by 7.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 756,383 shares of the medical instruments supplier’s stock valued at $99,956,000 after acquiring an additional 53,896 shares during the period. Finally, River Road Asset Management LLC grew its position in shares of ICU Medical by 207.0% during the 2nd quarter. River Road Asset Management LLC now owns 651,492 shares of the medical instruments supplier’s stock valued at $83,658,000 after acquiring an additional 439,263 shares during the period. 96.10% of the stock is currently owned by institutional investors.

ICU Medical Stock Down 2.3%

Shares of ICUI stock opened at $125.85 on Friday. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.39 and a quick ratio of 1.15. ICU Medical, Inc. has a one year low of $107.00 and a one year high of $160.29. The company’s fifty day moving average price is $147.98 and its 200-day moving average price is $138.00. The company has a market capitalization of $3.11 billion, a price-to-earnings ratio of 6,295.65, a PEG ratio of 1.86 and a beta of 0.79.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, February 19th. The medical instruments supplier reported $1.91 earnings per share for the quarter, topping the consensus estimate of $1.68 by $0.23. The company had revenue of $535.94 million during the quarter, compared to the consensus estimate of $541.20 million. ICU Medical had a net margin of 0.03% and a return on equity of 7.33%. ICU Medical’s quarterly revenue was down 14.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.11 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Sell-side analysts expect that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on ICUI. KeyCorp raised their target price on ICU Medical from $175.00 to $180.00 and gave the stock an “overweight” rating in a report on Friday, February 20th. Wall Street Zen raised ICU Medical from a “hold” rating to a “buy” rating in a report on Sunday, February 15th. Weiss Ratings restated a “sell (d-)” rating on shares of ICU Medical in a research report on Thursday, January 22nd. Finally, Piper Sandler lifted their price objective on ICU Medical from $172.00 to $178.00 and gave the company an “overweight” rating in a research report on Friday, February 20th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $179.33.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.